Jul. 14, 2020—An experimental coronavirus vaccine stimulated robust immune responses against SARS-CoV-2, the virus that causes COVID-19, and raised no serious safety concerns in an early-stage clinical trial.
Jul. 9, 2020—This week researchers at Vanderbilt University Medical Center (VUMC), the University of North Carolina at Chapel Hill and Gilead Sciences reported that remdesivir potently inhibited SARS-CoV-2, the virus which causes COVID-19, in human lung cell cultures and that it improved lung function in mice infected with the virus.
May. 14, 2020—From the front lines of patient care to collaborating with scientists across the globe searching for treatments and vaccines, Vanderbilt University Medical Center and Vanderbilt University researchers have been working for months to combat the COVID-19 pandemic.
Apr. 6, 2020—Researchers at Vanderbilt University Medical Center are playing a key role in the development of a potential new antiviral drug to treat COVID-19.
Feb. 28, 2020—Nine Vanderbilt faculty members who have been awarded endowed chairs were recently honored by Interim Chancellor and Provost Susan R. Wente, deans, colleagues and family members.
Jun. 29, 2017—A new antiviral drug candidate inhibits a broad range of coronaviruses, including the SARS and MERS coronaviruses, a multi-institutional team of investigators reports this week in Science Translational Medicine.
May. 12, 2016—Four physicians from Vanderbilt University Medical Center (VUMC) have been elected to membership in two of the nation’s oldest and most respected medical honor societies — the Association of American Physicians (AAP) and the American Society for Clinical Investigation (ASCI).
Feb. 18, 2016—The National Institutes of Health (NIH) has awarded Vanderbilt’s Department of Pediatrics a K12 training grant to support early career faculty to become physician-scientists, the first time the department has received such an award.
Feb. 24, 2015—Understanding the role that host membrane modification plays in coronavirus replication is essential for developing novel approaches to block the viruses that cause SARS and MERS.
Sep. 12, 2013—A coronavirus protein is required for replication of the viral genome and may be a good treatment target for SARS and other diseases caused by coronaviruses.
Nov. 12, 2012—Collaborating researchers at the University of North Carolina and Vanderbilt University have found that accelerating the rate of mutations in the coronavirus responsible for deadly severe acute respiratory syndrome (SARS) cripples the virus’s ability to cause disease in animals.
Dec. 14, 2011—Fourteen Vanderbilt researchers have been elected fellows of the American Association for the Advancement of Science (AAAS).